Publications by authors named "Javier Cortés"

100Publications

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.

Clin Breast Cancer 2020 Sep 30. Epub 2020 Sep 30.

Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2020.09.011DOI Listing
September 2020

ASCO 2020.

Breast Care (Basel) 2020 Aug 16;15(4):433-436. Epub 2020 Jul 16.

Breast Center Eastern Switzerland, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000510051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490662PMC
August 2020

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.

Cancer Res 2020 Sep 14. Epub 2020 Sep 14.

Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-20-1792DOI Listing
September 2020

Can we cure oligometastatic disease? A practical point of view.

Curr Opin Oncol 2020 Nov;32(6):568-574

Institute of Breast Cancer, Quiron Group, Barcelona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000684DOI Listing
November 2020

Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.

BioDrugs 2020 Oct;34(5):611-623

IOB Institute of Oncology, Quiron Group, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-020-00436-9DOI Listing
October 2020

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.

J Natl Compr Canc Netw 2020 08;18(8):1096-1104

Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2020.7550DOI Listing
August 2020

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.

Front Oncol 2020 10;10:1223. Epub 2020 Jul 10.

Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.01223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365943PMC
July 2020

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.

Sci Rep 2020 07 8;10(1):11203. Epub 2020 Jul 8.

Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-66980-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343788PMC
July 2020

Fibrous solitary tumor, a rare and ubiquitous neoplasy.

J Surg Case Rep 2020 Jun 18;2020(6):rjaa156. Epub 2020 Jun 18.

Department of Surgery, Radiology and Pathology, Verge dels Lliris Hospital, Polígono Carabanchel, s/n CP: 03804, Alcoy, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjaa156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304934PMC
June 2020

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.

Eur J Cancer 2020 08 4;135:62-65. Epub 2020 Jun 4.

Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Vall D´Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.05.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269953PMC
August 2020

Atezolizumab in the treatment of metastatic triple-negative breast cancer.

Expert Opin Biol Ther 2020 Sep 25;20(9):981-989. Epub 2020 May 25.

IOB Institute of Oncology, Quironsalud Group , Madrid & Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2020.1769063DOI Listing
September 2020

Pembrolizumab for Early Triple-Negative Breast Cancer.

N Engl J Med 2020 02;382(9):810-821

From Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Oncology Bureau Institute of Oncology, Quirón Group, Madrid, and Vall d'Hebron Institute of Oncology, Barcelona (J.C.) - both in Spain; Yale School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); Cedars-Sinai Medical Center, Los Angeles (H.M.); Kliniken Essen-Mitte, Essen (S.K.), the Institute of Pathology, Philipps-University Marburg and University of Marburg, Marburg (C.D.), the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Ludwig Maximilian University of Munich, University of Munich, Munich (N.H.), University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Erlangen (P.A.F.), and the Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin (M.U.) - all in Germany; the Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Center, Theme Cancer, Karolinska University Hospital, Solna, Sweden (J.B., T.F.); Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (Y.H.P.); Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney (R.H.); Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan (M.T.); the Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal (F.C.); Merck, Kenilworth, NJ (L.J., V.K., J.Z., G.A.); the National Cancer Center Singapore, Duke-National University of Singapore Medical School, Singapore (R.D.); and Baylor University Medical Center, Texas Oncology and US Oncology, Dallas (J.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910549DOI Listing
February 2020

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

N Engl J Med 2020 02 11;382(7):610-621. Epub 2019 Dec 11.

From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) - all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) - all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) - both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana-Farber Cancer Institute, Boston (I.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458671PMC
February 2020

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.

Breast J 2020 Jul 29;26(7):1347-1351. Epub 2019 Nov 29.

Leeds Institute of Medical Research at St James's, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13686DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496313PMC
July 2020

Clinical Implications of Extracellular HMGA1 in Breast Cancer.

Int J Mol Sci 2019 Nov 26;20(23). Epub 2019 Nov 26.

Vall D'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20235950DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928815PMC
November 2019

Breast cancer.

Nat Rev Dis Primers 2019 09 23;5(1):66. Epub 2019 Sep 23.

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41572-019-0111-2DOI Listing
September 2019

Window of Opportunity trials for biomarker discovery in breast cancer.

Curr Opin Oncol 2019 11;31(6):486-492

IOB Institute of Oncology, Quiron, Madrid.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000583DOI Listing
November 2019

The rise of oncology biosimilars: from process to promise.

Future Oncol 2019 Oct 23;15(28):3255-3265. Epub 2019 Aug 23.

Department of Medical Oncology, OB Institute of Oncology, Quironsalud Group, Calle Diego de Velázquez, 1, 28223 Pozuelo de Alarcón, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0145DOI Listing
October 2019

The safety of eribulin for the treatment of metastatic breast cancer.

Expert Opin Drug Saf 2019 May 20;18(5):347-355. Epub 2019 May 20.

a Medica Scientia Innovation Research (MedSIR) , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2019.1608946DOI Listing
May 2019

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations.

Int J Mol Sci 2019 Mar 1;20(5). Epub 2019 Mar 1.

BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/ Serrano 113 bis, 28006 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20051076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429128PMC
March 2019

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

Oncologist 2019 08 21;24(8):1041-1047. Epub 2018 Dec 21.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693696PMC
August 2019

CXCR4 antagonists for treatment of breast cancer.

Oncotarget 2018 Sep 11;9(71):33442-33443. Epub 2018 Sep 11.

Javier Cortés: Ramon y Cajal University Hospital, Madrid, Spain; Vall d´Hebron Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, QuironGroup, Madrid & Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173365PMC
September 2018

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.

Cancer Treat Rev 2018 Nov 21;70:190-198. Epub 2018 Aug 21.

Global Oncology, Eisai Inc., Andover, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.08.008DOI Listing
November 2018

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

J Clin Oncol 2018 Sep 20:JCO2017748392. Epub 2018 Sep 20.

Aditya Bardia, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Scott Cameron and Serena Liao, Novartis Institutes for BioMedical Research, Cambridge, MA; Marina Parton, The Royal Marsden Hospital, London, United Kingdom; Sherko Kümmel, Kliniken Essen-Mitte, Essen, Germany; Laura G. Estévez, Centro Integral Oncológico Clara Campal; Javier Cortés, University Hospital Ramón y Cajal, Madrid; Javier Cortés,Vall d'Hebron Institute of Oncology, Barcelona; Manuel Ruiz-Borrego, Hospital Universitario Virgen del Rocío, Seville; Paloma Martin-Martorell, Hospital Clínico Universitario de Valencia, Valencia; Rafael López, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Chiun-Sheng Huang, National Taiwan University Hospital, National Taiwan University College of Medicine; Shin-Cheh Chen, Chang Gung Memorial Hospital, Taipei, Republic of China; Melinda L. Telli, Stanford University School of Medicine, Stanford; Sara A. Hurvitz, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Roohi Ismail-Khan, Moffitt Cancer Center, Tampa, FL; Ingrid A. Mayer, Vanderbilt-Ingram Cancer Center, Nashville, TN; Daniel Carreon, Novartis Pharmaceuticals Corporation, East Hanover, NJ; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; and Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.8392
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.8392DOI Listing
September 2018

Is there a role for immunotherapy in HER2-positive breast cancer?

NPJ Breast Cancer 2018 15;4:21. Epub 2018 Aug 15.

1Ramon y Cajal University Hospital, Ctra, Colmenar Viejo km. 9,100, 28034 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-018-0072-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093898PMC
August 2018

Reply to K.S. Shohdy et al.

J Clin Oncol 2018 08 30;36(23):2458-2459. Epub 2018 May 30.

Tiffany A. Traina, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; and Javier Cortes, Ramon y Cajal University Hospital, Madrid, and Vall d'Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.8349
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.8349DOI Listing
August 2018

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Lancet Oncol 2018 06 26;19(6):812-824. Epub 2018 Apr 26.

Breast Cancer Unit and Gynaecological Tumours, Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Baselga Oncology Institute, Quiron Group, Madrid and Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30147-5DOI Listing
June 2018

The new world of biosimilars in oncology: Translation of data to the clinic.

Eur J Cancer 2018 06 18;96:125-127. Epub 2018 Apr 18.

Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.005DOI Listing
June 2018

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

J Clin Oncol 2018 03 26;36(9):884-890. Epub 2018 Jan 26.

Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d'Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.3495
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.3495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858523PMC
March 2018

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Cancer Treat Rev 2018 Feb 6;63:144-155. Epub 2017 Dec 6.

Medical Oncology Clinic, Institut Jules Bordet Universite Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.12.002DOI Listing
February 2018

Breast cancer in 2017: Spurring science, marking progress, and influencing history.

Nat Rev Clin Oncol 2018 02 12;15(2):79-80. Epub 2017 Dec 12.

Ramon y Cajal University Hospital, Carretera Colmenar Viejo km. 9,100, 28034 Madrid, Spain; at Vall d´Hebron Institute of Oncology, Calle Natzaret 115-117, 08035 Barcelona, Spain; and at Medica Scientia Innovation Research (MedSIR), Rambla Catalunya 2, 08007 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.191DOI Listing
February 2018

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.

Cancer Treat Rev 2017 Dec 12;61:53-60. Epub 2017 Oct 12.

MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston 77030, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.09.011DOI Listing
December 2017

Modulation of telomere protection by the PI3K/AKT pathway.

Nat Commun 2017 11 2;8(1):1278. Epub 2017 Nov 2.

Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-01329-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668434PMC
November 2017

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

Biochim Biophys Acta Rev Cancer 2017 Dec 20;1868(2):527-537. Epub 2017 Oct 20.

Ramon y Cajal University Hospital, Ctra. Colmenar Viejo km. 9, 100, 28034 Madrid, Spain; Baselga Institute of Oncology, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2017.10.003DOI Listing
December 2017

Advances in the management of HER2-positive early breast cancer.

Crit Rev Oncol Hematol 2017 Nov 4;119:113-122. Epub 2017 Oct 4.

University of Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.10.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662944PMC
November 2017